Drugs / MRTX1133
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05737706 | Mar 2023 → Mar 2025 | colorectal cancer, non-small cell lung carcinoma, pancreatic adenocarcinoma | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRTX1133 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05737706 ↗ |
| Action | Inhibit | “KRAS G12D Inhibitor” NCT05737706 ↗ |
| Target | KRAS | “KRAS G12D Inhibitor” NCT05737706 ↗ |